Pharmacosmos
This sponsor has funded 2 studies across 4 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 4492 | Finalised | A non-intervention trial of the time to relapse of iron deficiency anemia after standard treatment with a new intravenous iron (Monofer®)... | No | No |
| 7008 | Finalised | A non-interventional study of Diafer® (5% Iron Isomaltoside 1000) administered according to standard hospital practice and product labelling in... | No | No |
PAS by Risk Management Plan (RMP) requirement
Pharmacosmos
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Pharmacosmos
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Pharmacosmos
4 Study countries specified are the following:
- Denmark
- Norway
- Sweden
- United Kingdom